Nashville, Tennessee 37215, United States
Michael Zemel
2007
10
Private company
Series C
16.0
Hatteras Ventures
Genomic instability, Mitochondrial dysfunction
natural compound
NuSirt Biopharma, Inc. has developed a breakthrough technology platform that combines natural compounds with various pharmaceutical agents.
The company has protected the discovery and application of this broad based technology platform through an extensive IP portfolio that includes thirteen issued or allowed to date with corresponding patents pending globally. NuSirt has successfully conducted multiple clinical studies that have validated its discovery and demonstrated the value of its intellectual property.